Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 65 for “"Radioimmunotherapy"”.

  1. Fractionated radioimmunotherapy of non-Hodgkin's lymphoma

    <p>Impressive durable responses from clinical studies using higher myeloablative dose RIT followed by peripheral blood stem cell transplant (PBSCT) suggest that there may be a radiation dose response for RIT. With the development of rituximab, a chimeric mAb, multiple or fractionated treatments are …

    soton Download PDF for Fractionated radioimmunotherapy of non-Hodgkin's lymphoma (opens in a new tab)

  2. Developing radioimmunotherapy for osteosarcoma using comparative oncology

    … OS, making it a promising therapeutic target for radioimmunotherapy (RIT). RIT involves the use of an antibody labeled with an alpha- or beta- emitting radioisotope which delivers cytotoxic radiation to targeted cells. Our objective is to develop a novel, effective and safe treatment for OS using …

    sask Repository record for Developing radioimmunotherapy for osteosarcoma using comparative oncology (opens in a new tab)

  3. Optimization of radioimmunotherapy for non-Hodgkin's lymphoma

    <p><span >Radioimmunotherapy (RIT) has emerged as a new form of effective treatment for this disease. In this form of treatment, radionuclide-labelled monoclonal antibodies (mAbs) are able to deliver selective systemic irradiation by recognising tumour-associated antigens. Most recently, the use of …

    soton Download PDF for Optimization of radioimmunotherapy for non-Hodgkin's lymphoma (opens in a new tab)

  4. Metal-chelating Polymers for Auger Electron Radioimmunotherapy

    Radioimmunotherapy is a promising strategy for cancer treatment. The incorporation of metal-chelating polymers (MCPs) into radioimmunoconjugates (RICs) can increase the specific activities of RICs due to the multiple radioactive isotope binding sites provided by MCPs. This thesis describes the …

    toronto-retro Repository record for Metal-chelating Polymers for Auger Electron Radioimmunotherapy (opens in a new tab)

  5. Pembrolizumab-Based Radioimmunotherapy Against Primary Brain Tumors

    Glioblastoma is the most frequent primary brain tumor, with a dismal median survival rate of approximately 15 months despite the current standard of care that includes surgery, radiotherapy and chemotherapy. The recent success of immune checkpointinhibitors in treating metastatic melanoma and …

    creighton Repository record for Pembrolizumab-Based Radioimmunotherapy Against Primary Brain Tumors (opens in a new tab)

  6. Advancing Radioimmunotherapy for Brain Tumors Using In Vitro Assays

    … is undergoing phase I and II clinical trials in radioimmunotherapy for recurrent glioblastoma and high-grade glioma. However, with high potential may also exist unforeseen effects which may affect treatment outcomes. The purpose of this work is to bring these agents used in radioimmunotherapy …

    creighton Repository record for Advancing Radioimmunotherapy for Brain Tumors Using In Vitro Assays (opens in a new tab)

  7. Targeting regulatory T cells in experimental colon cancer with radioimmunotherapy

    … tumors. This makes CCR8 a promising target for radioimmunotherapy (RIT) to selectively eliminate ti-Treg cells. RIT allows for precise delivery of highly cytotoxic radionuclides to localized or systemic cancer deposits. In this study, we tested the hypothesis that using CCR8 as a target in RIT …

    sask Repository record for Targeting regulatory T cells in experimental colon cancer with radioimmunotherapy (opens in a new tab)

  8. PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer

    … can be radiolabeled for molecular imaging and radioimmunotherapy (RIT). This thesis aimed to develop a “theranostic” agent that could be used for both imaging and treatment of pancreatic tumours. The first study demonstrated the ability of 64Cu-panitumumab F(ab′)2 fragments to visualize …

    toronto-retro Repository record for PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer (opens in a new tab)

  9. Radioimmunotherapy in an Immunocompetent Tumor Model utilizing a 177Lu-mAb

    Radioimmunotherapy (RIT) is a therapeutic strategy in which radionuclides are conjugated to monoclonal antibodies that bind to tumor-associated antigens in the tumor, so that the decay of the radionuclide takes place inside the tumor. The aim of the research presented in this thesis was to …

    lund Repository record for Radioimmunotherapy in an Immunocompetent Tumor Model utilizing a 177Lu-mAb (opens in a new tab) Download PDF for Radioimmunotherapy in an Immunocompetent Tumor Model utilizing a 177Lu-mAb (opens in a new tab)

  10. Pretargeted cancer radioimmunotherapy and radioimaging using antibodies and antibody fragments

    … diagnosis and therapeutics. In traditional radioimmunotherapy (RIT), tumor targeting antibodies are directly conjugated with radioisotopes and depending on the radionuclides's properties, the direct labeled antibodies can be used for diagnostic or therapeutic purposes. However, one of the …

    missouri Repository record for Pretargeted cancer radioimmunotherapy and radioimaging using antibodies and antibody fragments (opens in a new tab)

  11. Pretargeted Radioimmunotherapy Utilizing the Inverse Electron Demand Diels-Alder Reaction

    Radioimmunotherapy capitalizes on the specificity and affinity of antibodies for their antigens to localize radioactivity at the tumor site. One limitation in using antibodies is their long circulation time, which can take days to weeks to fully clear from blood circulation. When a radioisotope is …

    cuny-grad Repository record for Pretargeted Radioimmunotherapy Utilizing the Inverse Electron Demand Diels-Alder Reaction (opens in a new tab)

  12. In vitro development of MUC1-CE Radioimmunotherapy for pancreatic ductal adenocarcinoma

    Radioimmunotherapy (RIT) uses radiolabelled antibodies, known as radioimmunoconjugates, to deliver cytotoxic doses of radiation directly to cancer cells. RIT may be beneficial in treating aggressive malignancies like pancreatic cancer (PC). This thesis explores the development and in vitro …

    adelaide Repository record for In vitro development of MUC1-CE Radioimmunotherapy for pancreatic ductal adenocarcinoma (opens in a new tab)

  13. IMMUNOHISTOCHEMISTRY AS A TOOL FOR MECHANISTIC STUDIES OF RADIOIMMUNOTHERAPY OF OSTEOSARCOMA

    … Radionuclide Therapy (TRT), specifically Radioimmunotherapy (RIT), as a novel treatment approach for OS. RIT utilises antibody molecules to deliver radiation to tumor cells, with promising applications in treating metastatic disorders. Notably, the cation-independent …

    sask Repository record for IMMUNOHISTOCHEMISTRY AS A TOOL FOR MECHANISTIC STUDIES OF RADIOIMMUNOTHERAPY OF OSTEOSARCOMA (opens in a new tab)

  14. Development of T Cell Targeting Radioimmunotherapy for Autoimmune and Oncology Applications

    … Here we report the development of antibody-based radioimmunotherapy (RIT) against the programmed cell death-1 (PD-1) and chemokine receptor 8 (CCR8) to target distinct T cell populations in autoimmune and oncology models, respectively. The murine experimental autoimmune encephalomyelitis (EAE) was …

    sask Repository record for Development of T Cell Targeting Radioimmunotherapy for Autoimmune and Oncology Applications (opens in a new tab)

  15. Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach

    … which are crucial aspects of antibody-based radioimmunotherapy (RIT). An innovative aspect of the study involved using 177Lu-labeled IF3 in mice with canine-patient-derived tumors, which showed high uptake in both the tumor and spleen, leading to significant inhibition of tumor growth. …

    sask Repository record for Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach (opens in a new tab)

  16. Bispecific Radioimmunoconjugates for Molecular Imaging and Radioimmunotherapy of HER2 Overexpressing Breast Cancer

    … one or more receptor for molecular imaging and radioimmunotherapy of BC. Trastuzumab Fab fragments were conjugated to heregulin (HRG) or epidermal growth factor (EGF) with a 24-mer polyethylene glycol (PEG) linker, and labeled with 111In or 177Lu. 111In-DTPA-Fab-PEG24-HRG and …

    toronto-retro Repository record for Bispecific Radioimmunoconjugates for Molecular Imaging and Radioimmunotherapy of HER2 Overexpressing Breast Cancer (opens in a new tab)

Page 1 of 4